PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery

Journal of Biomedical Informatics

Volumn 56, Issue , 2015, Pages 348-355

  Xu, Rong ^a   Wang, QuanQiu ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ThinTek LLC ^*  (United States)

Author keywords

Disease phenotype; Drug discovery; Drug repositioning; Schizophrenia; Systems biology

Indexed keywords

DRUG THERAPY; FORECASTING; KNOWLEDGE BASED SYSTEMS;

DISEASE PHENOTYPES; DRUG DISCOVERY; DRUG REPOSITIONING; SCHIZOPHRENIA; SYSTEMS BIOLOGY;

DISEASES;

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; HALOPERIDOL; LEVODOPA; LITHIUM; MEMANTINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PREDNISONE; QUETIAPINE; RISPERIDONE; SERTRALINE; VALPROIC ACID; ZIPRASIDONE;

ALGORITHM; ARTICLE; COMPARATIVE STUDY; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG MECHANISM; DRUG REPOSITIONING; FOOD AND DRUG ADMINISTRATION; HUMAN; MEASUREMENT ACCURACY; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; AREA UNDER THE CURVE; BIOLOGY; DEVICES; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; FACTUAL DATABASE; KNOWLEDGE BASE; PHENOTYPE; PROCEDURES; REPRODUCIBILITY; SOFTWARE; UNITED STATES;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG REPOSITIONING; KNOWLEDGE BASES; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SOFTWARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84938584604     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2015.06.027     Document Type: Article

References (54)

1. Collins P.Y., Patel V., Joestl S.S., March D., Insel T.R., Daar A.S., et al. Grand challenges in global mental health. Nature 2011, 475(7354):27-30.
2. Kessler R.C., Chiu W.T., Demler O., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiat. 2005, 762(6):617-627.
3. Mathers C., Fat D.M., Boerma J.T. The Global Burden of Disease: 2004 Update 2004, World Health Organization.
4. Sullivan P.F. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat. Med. 2012, 18(2):210-211.
5. Hyman S.E. Time for new schizophrenia Rx. Science 2014, 343(6176):1177.
6. Hyman S.E. Revolution stalled. Sci. Transl. Med. 2012, 4(155). 155cm11-155cm11.
7. Miller G. Is pharma running out of brainy ideas. Science 2010, 329(5991):502-504.
8. S.E. Hyman, Psychiatric Drug Development: Diagnosing a Crisis, in: Cerebrum: The Dana Forum on Brain Science, vol. 2013, Dana Foundation.
9. Mitchell P.B., Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bull. World Health Organ. 2000, 78(4):515-517.
10. Lopez-Munoz F., Alamo C., Cuenca E., Shen W.W., Clervoy P., Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann. Clin. Psychiatry 2005, 17(3):113-135.
11. R.A. Maxwell, S.B. Eckhardt, Drug Discovery: A Casebook and Analysis, Humana Press, Clifton, NJ, (p. xvii).
12. Dolgin E. Rapid antidepressant effects of ketamine ignite drug discovery. Nat. Med. 2013, 19(1):8.
13. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery 2004, 3(8):673-683.
14. Dudley J.T., Deshpande T., Butte A.J. Exploiting drugdisease relationships for computational drug repositioning. Briefings Bioinformatics 2011, 12(4):303-311.
15. Hurle M.R., Yang L., Xie Q., Rajpal D.K., Sanseau P., Agarwal P. Computational drug repositioning: from data to therapeutics. Clin. Pharmacol. Ther. 2013, 93(4):335-341.
16. Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Roth B.L. Predicting new molecular targets for known drugs. Nature 2009, 462(7270):175-181.
17. Kinnings S.L., Liu N., Buchmeier N., Tonge P.J., Xie L., Bourne P.E. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput. Biol. 2009, 5(7):e1000423.
18. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Golub T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935.
19. Sirota M., Dudley J.T., Kim J., Chiang A.P., Morgan A.A., Sweet-Cordero A., Butte A.J. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 2011, 3(96ra):77.
20. Dudley J.T., Sirota M., Shenoy M., Pai R.K., Roedder S., Chiang A.P., Butte A.J. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 2011, 3(96). 96ra76-96ra76.
21. Chiang A.P., Butte A.J. Systematic evaluation of drugdisease relationships to identify leads for novel drug uses. Clin. Pharmaco. Ther. 2009, 86(5):507-510.
22. Campillos M., Kuhn M., Gavin A.C., Jensen L.J., Bork P. Drug target identification using side-effect similarity. Science 2008, 321(5886):263-266.
23. Duran-Frigola M., Aloy P. Recycling side-effects into clinical markers for drug repositioning. Genome Med. 2012, 4(3).
24. Lounkine E., Keiser M.J., Whitebread S., Mikhailov D., Hamon J., Jenkins J.L., Urban L. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012, 486(7403):361-367.
25. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
26. Xu R., Wang Q. Large-scale extraction of drug-disease treatment pairs from biomedical literature for drug repurposing. BMC Bioinformatics 2013, 14(1):181.
27. Xu R., Li L., Wang Q. Towards building a disease-phenotype relationship knowledge base: large scale extraction of disease-manifestation relationship from literature. Bioinformatics 2013, 10.1093/bioinformatics/btt359.
28. Xu R., Wang Q. Automatic signal prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). J. Biomed. Inf. 2014, 171-177.
29. Robinson P.N., Kohler S., Bauer S., Seelow D., Horn D., Mundlos S. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am. J. Human Genet. 2008, 83(5):610-615.
30. Hamosh A., Scott A.F., Amberger J.S., Bocchini C.A., McKusick V.A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005, 33(suppl 1):D514-D517.
31. Robinson P.N., Kohler S., Oellrich A., Wang K., Mungall C.J., Lewis S.E., Smedley D. Improved exome prioritization of disease genes through cross-species phenotype comparison. Genome Res. 2014, 24(2):340-348.
32. Zhou X., Menche J., Barabasi A.L., Sharma A. Human symptomsdisease network. Nat. Commun. 2014, 5. 10.1038/ncomms5212.
33. Moreau Y., Tranchevent L.C. Computational tools for prioritizing candidate genes: boosting disease gene discovery. Nat. Rev. Genet. 2010, 13(8):523-536.
34. Gottlieb A., Stein G.Y., Ruppin E., Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol. Syst. Biol. 2011, 7(1):55.
35. Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004, 32(suppl 1):D267-D270.
36. Y. Chen, R. Xu, Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery, in: International Conference on Intelligent Biology and Medicine (ICIBM 2014), December 4-6, San Antonio, TX.
37. R. Xu, Q. Wang, L. Li, Genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat, In: International Conference on Intelligent Biology and Medicine (ICIBM 2014), December 4-6, San Antonio, TX.
38. ICD-10: International Statistical Classification of Diseases and Related Health Problems: 10th Revision, World Health Organization, 1992.
39. Manning C.D. Foundations of Statistical Natural Language Processing 1999, MIT Press. H. Schutze (Ed.).
40. F.J. Provost, T. Fawcett, R. Kohavi, The case against accuracy estimation for comparing induction algorithms, in: International Conference on Machine Learning (ICML), vol. 98, 1998, pp. 445-453.
41. J. Davis, E.S. Burnside, I. de Castro Dutra, D. Page, R. Ramakrishnan, V.S. Costa, J.W. Shavlik, View learning for statistical relational learning: with an application to mammography, in: International Joint Conference on Artificial Intelligence (IJCAI), 2006, pp. 677-683.
42. Davis J., Goadrich M. The relationship between Precision-Recall and ROC curves. Proceedings of the 23rd International Conference on Machine Learning 2005, 233-240. ACM.
43. World Health Organization: The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD), WHO, Norway.
44. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int. J. Neuropsychopharm. 2011, 14(07):997-1012.
45. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav. Immun. 2011, 25(8):1507-1518.
46. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11(7):680-684.
47. Sullivan P.F., Daly M.J., O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 2012, 13(8):537-551.
48. Wahlbeck K., Cheine M.V., Gilbody S., Ahonen J. Efficacy of Beta-blocker supplementation for schizophrenia: a systematic review of randomized trials. Schizophr. Res. 2000, 41(2):341-347.
49. Shek E., Bardhan S., Cheine M.V., Ahonen J., Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Schizophrenia Bull. 2010, (sbq089).
50. van den Buuse M., Zheng T.W., Walker L.L., Denton D.A. Angiotensin-converting enzyme (ACE) interacts with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice. Neurosci. Lett. 2005, 380(1):6-11.
51. Phillips I.M. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol. 1987, 49(1):413-433.
52. Domeney A.M. Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents. J. Psychiatry Neurosci. 1994, 19(1):46.
53. Xu R., Li L., Wang Q. dRiskKB: a large-scale disease-disease risk relationship knowledge base constructed from biomedical text. BMC Bioinformatics 2014, 15(1):105.
54. Chen Y., Zhang X., Zhang G.Q., Xu R. Comparative analysis of a novel disease phenotype network based on clinical manifestations. J. Biomed. Inform. 2015, 53:113-120. 10.1016/j.jbi.2014.09.007.